

GENOME THERAPEUTICS CORP

Form 8-K

January 09, 2004

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 9, 2004

GENOME THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

Massachusetts

**(State or other jurisdiction
of incorporation)**

0-10824

(Commission File Number)

04-2297484

**(I.R.S. Employer
Identification Number)**

100 Beaver Street

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

(781) 398-2300

(Registrant's telephone number, including area code)

Page 1 of 4 pages.

ITEM 5. OTHER EVENTS

On January 9, 2004, Genome Therapeutics Corp. issued a press release announcing that Genome Therapeutics and Amgen Inc. have concluded their research collaboration focused on discovering and developing therapeutics for bone diseases, which is attached hereto as Exhibit 99.1.

Item 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

99.1 Press Release issued by Genome Therapeutics Corp. on January 9, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By: /s/ STEVEN M. RAUSCHER

Name: Steven M. Rauscher

**Title: President and Chief Executive
Officer**

Date: January 9, 2004

EXHIBIT INDEX

Exhibit Number

Description

99.1

Press Release issued by Genome Therapeutics Corp. on January 9, 2004.